> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rapid Medical Clot Retriever Clearance
- URL: https://www.fdaweb.com/rapid-medical-clot-retriever-clearance/
- Published: 2021-03-25T12:00:00.000Z
- Updated: 2026-09-14T16:52:16.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5148969

FDA has cleared a Rapid Medical 510(k) for its TigerTriever revascularization device for use in treating ischemic stroke. The stent retriever offers intelligent control, enabling neuro interventionalists to better remove blood clots and restore blood flow in the brain following an ischemic event, according to the company.  

Clearance was based on data from the [TIGER Trial](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ahajournals.org%2Fdoi%2Fpdf%2F10.1161%2FSTROKEAHA.121.034436&esheet=52401640&newsitemid=20210325005722&lan=en-US&anchor=TIGER+Trial&index=2&md5=ab75759e6a5a0f9ceee97682fc063c68&ref=fdaweb.com), a 160-patient pivotal study that documented the device’s superiority over conventional stent retrievers, “achieving a statistically significant improvement in the ability to restore blood flow to the brain and excellent comparable safety metrics” the company says. “The trial also reveals the lowest-ever rate of clot fragmentation, suggesting that TigerTreiver’s control may provide better retention of the entire clot and minimize the potential for additional strokes caused by embolic particles.” Additionally, it says, the trial saw an 11-point improvement in revascularization over data from recent stent retriever trials.